Targeting Genomic Instability: An Achilles Heel in Cancer?
Free and open to the public
Dr. Kevin Mills is a molecular biologist who studies fundamental cancer processes. He received his B.A. in molecular biology from the University of Colorado, Boulder and completed his Ph.D. in Biology from the Massachusetts Institute of Technology. Dr. Mills completed a 5-year post-doctoral fellowship with Fred Alt at Harvard Medical School/Childrens Hospital in Boston, MA. Dr. Mills has since moved to The Jackson Laboratory where he is now an Associate Professor. He is also a member of the University of Maine Graduate School and holds a faculty appointment at Tufts University School of Medicine.
Dr. Mills’ laboratory is examining how nuclear architecture, genome structure and DNA repair mechanisms all influence this process as well as working with a mouse model of human leukemia/lymphoma to better understand the molecular pathobiology of the human disease. They are also investigating the connection between DNA damage and natural variations in aging, using the mouse as a model system to explore how genome stability control changes with age.
In 2012 Dr. Mills co-founded Cyteir Therapeutics, a biotechnology startup endeavoring to develop new cancer therapeutics that target genomic instability pathways.
Lunch will be provided.
Hosted by: John Streicher, Ph.D.
Address
St. Francis Room, Ketchum Library
United States